Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
193.3
USD
|
-0.54%
|
|
-8.82%
|
-16.44%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,406
|
1,719
|
1,449
|
5,179
|
4,568
|
4,059
|
-
|
-
|
Enterprise Value (EV)
1 |
966.7
|
1,436
|
1,179
|
4,869
|
4,051
|
3,965
|
4,175
|
3,803
|
P/E ratio
|
-16.7
x
|
-8.49
x
|
-5.79
x
|
-16.8
x
|
-11.6
x
|
-8.3
x
|
-13
x
|
37.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
49.7
x
|
11.5
x
|
4.36
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
48.5
x
|
11.9
x
|
4.08
x
|
EV / EBITDA
|
-10.2
x
|
-6.96
x
|
-4.87
x
|
-16.6
x
|
-10.7
x
|
-6.95
x
|
-8.76
x
|
-40.2
x
|
EV / FCF
|
-23.1
x
|
-9.09
x
|
-4.87
x
|
-16.6
x
|
-12.4
x
|
-8.92
x
|
-12.3
x
|
-39.5
x
|
FCF Yield
|
-4.32%
|
-11%
|
-20.6%
|
-6.01%
|
-8.04%
|
-11.2%
|
-8.13%
|
-2.53%
|
Price to Book
|
3.37
x
|
7.18
x
|
7.15
x
|
26.6
x
|
11.3
x
|
-38.8
x
|
-11.9
x
|
31.2
x
|
Nbr of stocks (in thousands)
|
15,429
|
15,466
|
17,097
|
17,842
|
19,743
|
20,994
|
-
|
-
|
Reference price
2 |
91.11
|
111.2
|
84.74
|
290.2
|
231.4
|
193.3
|
193.3
|
193.3
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
81.74
|
351.5
|
931.4
|
EBITDA
1 |
-94.86
|
-206.2
|
-242.1
|
-293.1
|
-380
|
-570.3
|
-476.6
|
-94.64
|
EBIT
1 |
-94.97
|
-206.7
|
-242.5
|
-293.6
|
-380.5
|
-495.7
|
-320.6
|
173.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-606.52%
|
-91.22%
|
18.63%
|
Earnings before Tax (EBT)
1 |
-83.95
|
-202.2
|
-241.8
|
-295.4
|
-373.6
|
-461.6
|
-288.8
|
148.1
|
Net income
1 |
-83.95
|
-202.2
|
-241.8
|
-295.4
|
-373.6
|
-458.8
|
-296.2
|
136.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-561.31%
|
-84.25%
|
14.66%
|
EPS
2 |
-5.450
|
-13.09
|
-14.63
|
-17.23
|
-19.99
|
-23.28
|
-14.82
|
5.167
|
Free Cash Flow
1 |
-41.8
|
-157.9
|
-242.3
|
-292.5
|
-325.7
|
-444.4
|
-339.3
|
-96.37
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-543.75%
|
-96.53%
|
-10.35%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3.974
|
25.64
|
51.29
|
40.45
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-78.21
|
-
|
-
|
-
|
-128.7
|
-138
|
-141.7
|
-135.3
|
-
|
EBIT
1 |
-63.16
|
-64.6
|
-57.59
|
-70.27
|
-80.41
|
-85.3
|
-78.34
|
-86.45
|
-98.53
|
-117.2
|
-130.1
|
-140.3
|
-131.9
|
-113.4
|
-132.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,531.4%
|
-514.42%
|
-220.98%
|
-326.67%
|
Earnings before Tax (EBT)
1 |
-63.1
|
-64.55
|
-57.52
|
-70.73
|
-81.2
|
-85.9
|
-76.9
|
-85.8
|
-98.74
|
-112.2
|
-124.8
|
-135.5
|
-123.4
|
-101
|
-110.4
|
Net income
1 |
-63.1
|
-64.55
|
-57.52
|
-70.73
|
-81.2
|
-85.9
|
-76.9
|
-85.8
|
-98.74
|
-112.2
|
-123.1
|
-131.5
|
-121.2
|
-102.1
|
-110.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,309.49%
|
-472.7%
|
-199.13%
|
-272.9%
|
EPS
2 |
-3.790
|
-3.790
|
-3.360
|
-4.140
|
-4.750
|
-4.980
|
-4.230
|
-4.690
|
-5.340
|
-5.680
|
-6.197
|
-6.544
|
-6.104
|
-5.126
|
-6.252
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
2/24/22
|
5/9/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/9/23
|
8/8/23
|
11/6/23
|
2/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
116
|
-
|
Net Cash position
1 |
439
|
284
|
270
|
309
|
517
|
93.5
|
-
|
256
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.2439
x
|
-
|
Free Cash Flow
1 |
-41.8
|
-158
|
-242
|
-293
|
-326
|
-444
|
-339
|
-96.4
|
ROE (net income / shareholders' equity)
|
-18.8%
|
-61.6%
|
-111%
|
-
|
-124%
|
-220%
|
10.9%
|
-257%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
27.00
|
15.50
|
11.90
|
10.90
|
20.40
|
-4.980
|
-16.30
|
6.200
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
-17.10
|
-13.90
|
-
|
Capex
1 |
0.17
|
0.33
|
0.21
|
0.22
|
1.48
|
2.63
|
3.02
|
2.89
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
3.22%
|
0.86%
|
0.31%
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
193.3
USD Average target price
377.1
USD Spread / Average Target +95.04% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.44% | 4.06B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|